Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16520101,extraction recoveries,"The average extraction recoveries of MGN and BPA from rat plasma were 98.6 and 97.4%, respectively.",Determination of mitiglinide in rat plasma by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16520101/),%,98.6,51128,DB01252,Mitiglinide
,16520101,extraction recoveries,"The average extraction recoveries of MGN and BPA from rat plasma were 98.6 and 97.4%, respectively.",Determination of mitiglinide in rat plasma by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16520101/),%,97.4,51129,DB01252,Mitiglinide
,28676080,terminal elimination half-life (t 1/2),The terminal elimination half-life (t 1/2) was 1.69 ± 0.16 h and the CL/F was 7.80 ± 1.84 L/h.,Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28676080/),h,1.69,102124,DB01252,Mitiglinide
,28676080,CL/F,The terminal elimination half-life (t 1/2) was 1.69 ± 0.16 h and the CL/F was 7.80 ± 1.84 L/h.,Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28676080/),[l] / [h],7.80,102125,DB01252,Mitiglinide
,25316572,urinary excretion,"Although urinary excretion of ipragliflozin is low (approximately 1 %), tubular concentration of free ipragliflozin is adequate to provide pharmacological activities.",Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25316572/),%,1,120234,DB01252,Mitiglinide
,21517925,T(max),"Food intake was associated with decreases in C(max) by 60·4% to 65·2% in the three dose groups and greatly delayed T(max) [0·36(Standard deviation 0·16) vs. 1·75(0·92) hours with 5 mg, 0·29(0·19) vs. 1·97(0·81) hours with 10 mg and 0·30(0·10) vs. 1·18(0·68) hours with 20 mg; all, P < 0·05].",The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass-spectrometric (UPLC-MS/MS) method for such studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21517925/),h,0·36,133079,DB01252,Mitiglinide
,21517925,T(max),"Food intake was associated with decreases in C(max) by 60·4% to 65·2% in the three dose groups and greatly delayed T(max) [0·36(Standard deviation 0·16) vs. 1·75(0·92) hours with 5 mg, 0·29(0·19) vs. 1·97(0·81) hours with 10 mg and 0·30(0·10) vs. 1·18(0·68) hours with 20 mg; all, P < 0·05].",The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass-spectrometric (UPLC-MS/MS) method for such studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21517925/),h,1·75,133080,DB01252,Mitiglinide
,21517925,T(max),"Food intake was associated with decreases in C(max) by 60·4% to 65·2% in the three dose groups and greatly delayed T(max) [0·36(Standard deviation 0·16) vs. 1·75(0·92) hours with 5 mg, 0·29(0·19) vs. 1·97(0·81) hours with 10 mg and 0·30(0·10) vs. 1·18(0·68) hours with 20 mg; all, P < 0·05].",The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass-spectrometric (UPLC-MS/MS) method for such studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21517925/),h,0·29,133081,DB01252,Mitiglinide
,21517925,T(max),"Food intake was associated with decreases in C(max) by 60·4% to 65·2% in the three dose groups and greatly delayed T(max) [0·36(Standard deviation 0·16) vs. 1·75(0·92) hours with 5 mg, 0·29(0·19) vs. 1·97(0·81) hours with 10 mg and 0·30(0·10) vs. 1·18(0·68) hours with 20 mg; all, P < 0·05].",The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass-spectrometric (UPLC-MS/MS) method for such studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21517925/),h,1·97,133082,DB01252,Mitiglinide
,21517925,T(max),"Food intake was associated with decreases in C(max) by 60·4% to 65·2% in the three dose groups and greatly delayed T(max) [0·36(Standard deviation 0·16) vs. 1·75(0·92) hours with 5 mg, 0·29(0·19) vs. 1·97(0·81) hours with 10 mg and 0·30(0·10) vs. 1·18(0·68) hours with 20 mg; all, P < 0·05].",The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass-spectrometric (UPLC-MS/MS) method for such studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21517925/),h,0·30,133083,DB01252,Mitiglinide
,21517925,T(max),"Food intake was associated with decreases in C(max) by 60·4% to 65·2% in the three dose groups and greatly delayed T(max) [0·36(Standard deviation 0·16) vs. 1·75(0·92) hours with 5 mg, 0·29(0·19) vs. 1·97(0·81) hours with 10 mg and 0·30(0·10) vs. 1·18(0·68) hours with 20 mg; all, P < 0·05].",The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass-spectrometric (UPLC-MS/MS) method for such studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21517925/),h,1·18,133084,DB01252,Mitiglinide
,19721250,diameter,"The weight, the diameter and the hardness of the obtained tablet were 416.1 mg, 10 mmpsi, about 60 N, respectively.",Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721250/),mmpsi,10,149179,DB01252,Mitiglinide
,19721250,hardness,"The weight, the diameter and the hardness of the obtained tablet were 416.1 mg, 10 mmpsi, about 60 N, respectively.",Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721250/),,60,149180,DB01252,Mitiglinide
,19721250,bioavailability,"An in vivo single oral administration study using normal beagle dogs showed the bioavailability value of the obtained nateglinide dry coated tablets against nateglinide immediate release tablets was 73.6%, although the value of nateglinide controlled release tablets containing enteric coated granules was 57.2-60.8%.",Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721250/),%,73.6,149181,DB01252,Mitiglinide
,19721250,bioavailability,"An in vivo single oral administration study using normal beagle dogs showed the bioavailability value of the obtained nateglinide dry coated tablets against nateglinide immediate release tablets was 73.6%, although the value of nateglinide controlled release tablets containing enteric coated granules was 57.2-60.8%.",Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721250/),%,57.2-60.8,149182,DB01252,Mitiglinide
,18318018,flow rate,The chromatographic separation was performed on an Agilent Zorbax Eclipse Plus C(18) column with a mobile phase of methanol-10 mm ammonium acetate solution at a flow rate of 0.3 mL/min.,Liquid chromatography/electrospray ionization tandem mass spectrometry for the quantification of mitiglinide in human plasma: validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318018/),[ml] / [min],0.3,174946,DB01252,Mitiglinide
,18486570,flow rate,"The separation was performed on an ACQUITY UPLCtrade mark BEH C(18) column (50 mm x 2.1 mm, i.d., 1.7 microm) with the mobile phase consisting of methanol and 10 mmol/L ammonium acetate (65:35, v/v) at a flow rate of 0.25 mL/min.",Quantitative determination of mitiglinide in human plasma by ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18486570/),[ml] / [min],0.25,189896,DB01252,Mitiglinide
,29948984,entrapment efficiency,"Results revealed that the optimized MTG microsponge was successfully formulated with high production yield (61.61% ± 0.6), entrapment efficiency (77.7% ±1.37), and particle size of 192.76 μm and it remained buoyant over simulated gastric fluid for 24 h with high percentage of in vitro buoyancy (91.01% ± 2.5).",Gastroretentive Microsponge as a Promising Tool for Prolonging the Release of Mitiglinide Calcium in Type-2 Diabetes Mellitus: Optimization and Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29948984/),%,77.7,253630,DB01252,Mitiglinide
,29948984,cumulative % release,"Moreover, it sustained the in vitro drug release with cumulative % release of 83.74 ± 1.5 after 24 h.",Gastroretentive Microsponge as a Promising Tool for Prolonging the Release of Mitiglinide Calcium in Type-2 Diabetes Mellitus: Optimization and Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29948984/),,83.74,253631,DB01252,Mitiglinide
